These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26158845)

  • 1. The Diagnostic Accuracy of the M2 Pyruvate Kinase Quick Stool Test--A Rapid Office Based Assay Test for the Detection of Colorectal Cancer.
    Sithambaram S; Hilmi I; Goh KL
    PLoS One; 2015; 10(7):e0131616. PubMed ID: 26158845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Performance of a Fecal Tumor M2-PK Rapid Kit Using Stool Specimens for Detection of Colorectal Tumors.
    Cho CH; Kim J; Jang MA; Lee BJ; Park JJ; Lim CS
    Ann Clin Lab Sci; 2016; 46(2):154-60. PubMed ID: 27098621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening.
    Abdullah M; Rani AA; Simadibrata M; Fauzi A; Syam AF
    Acta Med Indones; 2012 Apr; 44(2):94-9. PubMed ID: 22745138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
    Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
    Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Faecal Pyruvate Kinase Isoenzyme Type M2 (Faecal M2PK Quick) Test in Detection of Colorectal Adenoma and Adenocarcinoma Among High-Risk Malaysian Population.
    Mohd Suan MA; Ng YZ; Henry GF; Md Said R; Kollanthavelu S; Mustapha MI; Hoe CH; Lee CK; Rajamanickam P; Ismail I; Chan HK; Abu Hassan MR
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3183-3186. PubMed ID: 37774070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Fecal M2PK as a Diagnostic Marker in Colorectal Cancer.
    Dabbous HK; Mohamed YAE; El-Folly RF; El-Talkawy MD; Seddik HE; Johar D; Sarhan MA
    J Gastrointest Cancer; 2019 Sep; 50(3):442-450. PubMed ID: 29626277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia.
    Shastri YM; Naumann M; Oremek GM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein JM
    Int J Cancer; 2006 Dec; 119(11):2651-6. PubMed ID: 16929517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum.
    Rutka M; Bor R; Bálint A; Fábián A; Milassin Á; Nagy F; Szepes Z; Szűcs M; Tiszlavicz L; Farkas K; Molnár T
    Mediators Inflamm; 2016; 2016():2492081. PubMed ID: 27413251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
    Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
    N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of different stool tests for the detection of cancer of the colon].
    Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
    Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):851-3. PubMed ID: 12820312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD; Toepler M; Ngoumou B; Rupp J; Kloer HU
    Anticancer Res; 2003; 23(2A):855-7. PubMed ID: 12820313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.
    Tonus C; Neupert G; Sellinger M
    World J Gastroenterol; 2006 Nov; 12(43):7007-11. PubMed ID: 17109496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal pyruvate kinase-M2 (tumor M2-PK) measurement: a new screening concept for colorectal cancer.
    Ewald N; Schaller M; Bayer M; Akinci A; Bretzel RG; Kloer HU; Hardt PD
    Anticancer Res; 2007; 27(4A):1949-52. PubMed ID: 17649802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
    Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
    Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical significance of blood and fecal tumor M2-pyruvate kinase expression in patients with colorectal cancer].
    Li Y; Wang JJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):2087-9. PubMed ID: 22200720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.